BRPI0520330B8 - adjuvante a base de ácido polinosínico-policitidílico - Google Patents
adjuvante a base de ácido polinosínico-policitidílicoInfo
- Publication number
- BRPI0520330B8 BRPI0520330B8 BRPI0520330A BRPI0520330A BRPI0520330B8 BR PI0520330 B8 BRPI0520330 B8 BR PI0520330B8 BR PI0520330 A BRPI0520330 A BR PI0520330A BR PI0520330 A BRPI0520330 A BR PI0520330A BR PI0520330 B8 BRPI0520330 B8 BR PI0520330B8
- Authority
- BR
- Brazil
- Prior art keywords
- adjuvant
- eliciting
- immune response
- present
- polynosinic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
adjuvante a base de ácido polinosínico-policitidílico. mais particularmente a presente invenção refere-se a uma composição adjuvante polinucleotídica e métodos de uso para a obtenção de uma resposta imunológica. a presente invenção também se refere a uma composição imunogênica que compreende a composição adjuvante polinucleotídica em conjunto com um antigeno (por exemplo, na forma de uma vacina). as composições adjuvantes da invenção possuem propriedades fisicas específicas (por exemplo, peso molecular, concentração e ph) que abordam a necessidade de um adjuvante seguro para a obtenção de uma maior resposta imunológica. a presente invenção também contempla métodos de uso das referidas composições adjuvantes, especificamente para a obtenção de uma resposta imunológica a um composto antigênico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2005/000810 WO2006131023A1 (en) | 2005-06-08 | 2005-06-08 | Polyinosinic acid-polycytidylic acid-based adjuvant |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0520330A2 BRPI0520330A2 (pt) | 2009-05-05 |
BRPI0520330B1 BRPI0520330B1 (pt) | 2018-04-24 |
BRPI0520330B8 true BRPI0520330B8 (pt) | 2021-05-25 |
Family
ID=37498098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0520330A BRPI0520330B8 (pt) | 2005-06-08 | 2005-06-08 | adjuvante a base de ácido polinosínico-policitidílico |
Country Status (18)
Country | Link |
---|---|
US (2) | US7838017B2 (pt) |
EP (1) | EP1898948B1 (pt) |
JP (1) | JP2008542405A (pt) |
KR (1) | KR101203401B1 (pt) |
CN (1) | CN1997391A (pt) |
AT (1) | ATE539767T1 (pt) |
AU (1) | AU2005332599B2 (pt) |
BR (1) | BRPI0520330B8 (pt) |
CA (1) | CA2605583C (pt) |
DK (1) | DK1898948T3 (pt) |
ES (1) | ES2380481T3 (pt) |
IL (1) | IL187616A (pt) |
MX (1) | MX2007015639A (pt) |
MY (1) | MY146412A (pt) |
PL (1) | PL1898948T3 (pt) |
RU (1) | RU2383552C2 (pt) |
WO (1) | WO2006131023A1 (pt) |
ZA (1) | ZA200709747B (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1898948T3 (pl) * | 2005-06-08 | 2012-06-29 | Yisheng Biopharma Singapore Pte Ltd | Adiuwant na bazie kwasu poliinozynowego i policytydylowego |
US20070166239A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
US20070166800A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
WO2008133595A1 (en) * | 2007-04-26 | 2008-11-06 | Newbiomed Pika Pte Ltd | Compositions and methods for stimulating an immune response in-vivo and in-vitro |
US20090090367A1 (en) * | 2007-10-03 | 2009-04-09 | Hurley Scott B | Method of contraception |
KR100900837B1 (ko) * | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물 |
CN101890161B (zh) * | 2008-10-07 | 2014-07-23 | 郝国荣 | 聚核苷酸组合物佐剂 |
CN101780279B (zh) * | 2009-12-22 | 2012-07-11 | 中山大学中山眼科中心 | Toll-like receptor-3激动剂在制备促进伤口愈合的药物中的应用 |
US8569255B2 (en) | 2011-02-02 | 2013-10-29 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Post-exposure therapy of influenza A infections |
WO2013087083A1 (en) * | 2011-12-15 | 2013-06-20 | Biontech Ag | Particles comprising single stranded rna and double stranded rna for immunomodulation |
US10172960B2 (en) | 2011-12-15 | 2019-01-08 | Biontech Ag | Particles comprising single stranded RNA and double stranded RNA for immunomodulation |
BR112014026957A8 (pt) | 2012-05-03 | 2018-01-16 | Janssen R&D Ireland | micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior |
CN102949717A (zh) * | 2012-07-06 | 2013-03-06 | 中国疾病预防控制中心病毒病预防控制所 | 一种含poly I:C佐剂的新型乙肝疫苗制剂 |
GB201318862D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
GB201318858D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
US20170340727A1 (en) * | 2014-12-23 | 2017-11-30 | Yisheng Biopharma (Singapore) Pte Ltd | A Rabies Composition Comprising Pika Adjuvant |
CN114632091A (zh) | 2016-04-01 | 2022-06-17 | 依生生物制药(新加坡)私人有限公司 | 用于治疗癌症的含有聚核苷酸的药物组合物 |
CN109125264B (zh) * | 2017-06-19 | 2020-10-30 | 林海祥 | 一种抗感染抗肿瘤的粘膜免疫制剂 |
AU2018313636A1 (en) * | 2017-08-10 | 2020-03-26 | Yisheng Biopharma (Singapore) Pte Ltd | A composition for treating and/or preventing hepatitis B virus infection and the use thereof |
EP3556398A1 (en) * | 2018-04-16 | 2019-10-23 | Croda Denmark A/S | Phytates for use as a biomolecules delivery or adsorption system |
CA3105283A1 (en) * | 2018-06-29 | 2020-01-02 | Xinfu (Beijing) Medical Technology Co., Ltd. | Method for preparing composite for enhancing immune response |
CN109078180B (zh) * | 2018-06-29 | 2019-05-31 | 信福(北京)医药科技有限公司 | 用于增强免疫响应的复合物 |
CN109701011B (zh) * | 2019-02-26 | 2022-04-05 | 苏文全 | 疫苗复合佐剂系统及其在抗原中的应用 |
KR20230013133A (ko) * | 2020-05-29 | 2023-01-26 | 베이징 이셍 바이오테크놀로지 컴퍼니 엘티디. | 폴리뉴클레오타이드를 포함하는 약물조성물 및 그 covid-19 예방 또는 치료에 사용되는 용도 |
WO2024102079A1 (en) * | 2022-11-09 | 2024-05-16 | Zeno Therapeutics Pte Ltd | Compositions comprising polyinosinic-polycytidylic acid, epstein-barr (ebv) virus-like particles and ebv-specific car-t cells for improving immune cell therapy |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3692899A (en) | 1969-12-17 | 1972-09-19 | Us Health Education & Welfare | Inhibition of transplanted tumor growth by polyinosinic-polycytidylic acid in mice |
US3666646A (en) | 1970-05-15 | 1972-05-30 | Merck & Co Inc | Reduction of molecular weight in polynucleotides using ultrasonic radiation |
US4124702A (en) | 1971-07-06 | 1978-11-07 | Merck & Co., Inc. | Polynucleotides active as inducers of interferon production in living animal cells |
US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
US4186194A (en) | 1973-10-23 | 1980-01-29 | Agence Nationale De Valorisation De La Recherche (Anvar) | Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents |
US3952097A (en) | 1974-09-27 | 1976-04-20 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid |
US4024241A (en) | 1974-09-27 | 1977-05-17 | The United States Of America As Represented By The Secretary Of Health, Education And Welfare | Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid |
FR2321896A1 (fr) | 1975-08-29 | 1977-03-25 | Anvar | Agents adjuvants immunologiques actifs en solution aqueuse |
US4153684A (en) | 1976-03-10 | 1979-05-08 | Agence Nationale De Valorisation De La Recherche (Anvar) | Immunizing and anti-infectious adjuvant agents constituted by N-acetyl-muramyl-L-alanyl-D-glutamic acid derivatives |
US4082736A (en) | 1976-04-26 | 1978-04-04 | Syntex (U.S.A.) Inc. | Novel immunological adjuvant compounds and methods of preparation thereof |
US4082735A (en) | 1976-04-26 | 1978-04-04 | Syntex (U.S.A.) Inc. | Novel immunological adjuvant compounds and methods of preparation thereof |
GB1563561A (en) | 1976-06-23 | 1980-03-26 | Daiichi Seiyaku Co | Muramyldipeptide derivatives and process for the preparation thereof |
FR2368282A1 (fr) | 1976-10-22 | 1978-05-19 | Anvar | Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine |
US4140761A (en) | 1977-04-11 | 1979-02-20 | The United States Of America As Represented By The Department Of Health, Education & Welfare | Modification of hepatitis B virus infection in chronic carriers of hepatitis B surface antigen |
JPS55111499A (en) | 1979-02-21 | 1980-08-28 | Takeda Chem Ind Ltd | Glucosamine derivative and its preparation |
CA1185237A (en) | 1979-02-28 | 1985-04-09 | Yuichi Yamamura | 6-deoxyglucosamine-peptide derivatives, their production and use |
NZ194880A (en) | 1979-09-17 | 1983-07-15 | Merck & Co Inc | Interferon-inducing composition containing modified polyriboinosinic-polyribocytidylic acid |
US4349538A (en) | 1979-12-07 | 1982-09-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid |
FR2476488A2 (fr) | 1980-02-25 | 1981-08-28 | Government Us America | Nouveau complexe hydrophile, resistant aux nucleases, d'acide polyriboinosinique-polyribocytidylique, son procede de preparation et son application comme inducteur d'interferon |
JPS572220A (en) | 1980-06-09 | 1982-01-07 | Toray Ind Inc | Production of interferon |
US4389395A (en) | 1981-01-09 | 1983-06-21 | Lerner A Martin | Low molecular weight complex of polyriboinosinic-polyribocytidylic acid and method of inducing interferon |
ATE61935T1 (de) | 1985-02-07 | 1991-04-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von mikrokapseln. |
US4857315A (en) | 1986-09-29 | 1989-08-15 | Mount Sinai Hospital Corporation | Compositions containing golgi alpha-mannosidase II inhibitors |
JPH01186818A (ja) | 1988-01-18 | 1989-07-26 | Yamasa Shoyu Co Ltd | ポリリボイノシン酸・ポリリボシチジル酸・ポリ−l−リジン複合体製剤 |
CN1056315C (zh) | 1993-05-31 | 2000-09-13 | 林海祥 | 聚肌胞复合物免疫佐剂及含有该佐剂的疫苗 |
US6096291A (en) | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
CA2203843C (en) | 1997-04-28 | 2013-07-23 | Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence | Liposome-encapsulated poly iclc |
US6514948B1 (en) | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
JP4817625B2 (ja) | 2003-08-11 | 2011-11-16 | 一般財団法人阪大微生物病研究会 | 粘膜免疫誘導アジュバントを含む新規ワクチン |
WO2005105838A2 (en) | 2004-04-28 | 2005-11-10 | Paradigm Therapeutics Limited | Ion channel |
PL1898948T3 (pl) | 2005-06-08 | 2012-06-29 | Yisheng Biopharma Singapore Pte Ltd | Adiuwant na bazie kwasu poliinozynowego i policytydylowego |
US20070166239A1 (en) | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
US20070166800A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
-
2005
- 2005-06-08 PL PL05751955T patent/PL1898948T3/pl unknown
- 2005-06-08 CN CNA2005800150972A patent/CN1997391A/zh active Pending
- 2005-06-08 WO PCT/CN2005/000810 patent/WO2006131023A1/en active Application Filing
- 2005-06-08 AU AU2005332599A patent/AU2005332599B2/en active Active
- 2005-06-08 ES ES05751955T patent/ES2380481T3/es active Active
- 2005-06-08 EP EP05751955A patent/EP1898948B1/en active Active
- 2005-06-08 JP JP2008515024A patent/JP2008542405A/ja active Pending
- 2005-06-08 US US10/551,847 patent/US7838017B2/en active Active
- 2005-06-08 KR KR1020077027997A patent/KR101203401B1/ko active IP Right Grant
- 2005-06-08 MX MX2007015639A patent/MX2007015639A/es active IP Right Grant
- 2005-06-08 BR BRPI0520330A patent/BRPI0520330B8/pt active IP Right Grant
- 2005-06-08 RU RU2007149551/13A patent/RU2383552C2/ru active
- 2005-06-08 DK DK05751955.5T patent/DK1898948T3/da active
- 2005-06-08 AT AT05751955T patent/ATE539767T1/de active
- 2005-06-08 CA CA2605583A patent/CA2605583C/en active Active
-
2006
- 2006-05-26 MY MYPI20062439A patent/MY146412A/en unknown
-
2007
- 2007-11-13 ZA ZA200709747A patent/ZA200709747B/xx unknown
- 2007-11-25 IL IL187616A patent/IL187616A/en active IP Right Grant
-
2010
- 2010-04-13 US US12/759,287 patent/US8303965B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN1997391A (zh) | 2007-07-11 |
KR101203401B1 (ko) | 2012-11-22 |
IL187616A (en) | 2014-02-27 |
EP1898948A1 (en) | 2008-03-19 |
WO2006131023A1 (en) | 2006-12-14 |
PL1898948T3 (pl) | 2012-06-29 |
ES2380481T3 (es) | 2012-05-14 |
EP1898948B1 (en) | 2012-01-04 |
BRPI0520330A2 (pt) | 2009-05-05 |
CA2605583A1 (en) | 2006-12-14 |
AU2005332599A1 (en) | 2006-12-14 |
AU2005332599A8 (en) | 2008-03-20 |
US7838017B2 (en) | 2010-11-23 |
AU2005332599B2 (en) | 2012-02-16 |
EP1898948A4 (en) | 2008-07-16 |
US20100297176A1 (en) | 2010-11-25 |
BRPI0520330B1 (pt) | 2018-04-24 |
ZA200709747B (en) | 2008-11-26 |
DK1898948T3 (da) | 2012-04-23 |
MX2007015639A (es) | 2008-02-15 |
MY146412A (en) | 2012-08-15 |
RU2383552C2 (ru) | 2010-03-10 |
ATE539767T1 (de) | 2012-01-15 |
IL187616A0 (en) | 2008-03-20 |
RU2007149551A (ru) | 2009-07-10 |
CA2605583C (en) | 2013-05-28 |
KR20080016592A (ko) | 2008-02-21 |
US8303965B2 (en) | 2012-11-06 |
JP2008542405A (ja) | 2008-11-27 |
US20070160632A1 (en) | 2007-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0520330B8 (pt) | adjuvante a base de ácido polinosínico-policitidílico | |
MY150706A (en) | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant | |
CO6260103A2 (es) | Composiciones que comprenden antigenos neumococidos | |
MY143347A (en) | Mucosal immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant | |
DK1635863T3 (da) | Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål | |
ATE426412T1 (de) | Adjuvante influenza-vakzine | |
MX2019008303A (es) | Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika. | |
WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
NZ621834A (en) | Novel adjuvant compositions | |
PT2486938T (pt) | Composição para vacina contendo adjuvante sintético | |
WO2009143457A3 (en) | Vaccine composition containing synthetic adjuvant | |
WO2006136460A8 (en) | New adjuvant | |
WO2008148057A3 (en) | Cationic lipids compositions and methods for enhancing immune responses to vaccines | |
WO2008008541A3 (en) | Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes | |
EA201200538A1 (ru) | Арабиногалактан для повышения приобретенного иммунного ответа | |
WO2007120860A3 (en) | Nanoemulsion vaccines | |
WO2007028985A3 (en) | Adjuvanted vaccine | |
CU23720A3 (es) | Adyuvante basado en ácido poliinosínico-ácido policitidílico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: YISHENG BIOPHARMA (SINGAPORE) PTE LTD (SG) |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |